Sotalol, a non-selective β-adrenergic blocking agent classified as a class III antiarrhythmic agent due to its predominant potassium channel blocking effect is used for the treatment of supraventricular arrhythmias, atrial fibrillation/flutter as well as for the management of ventricular arrhythmias [243]. This evidence concerns the gene KCNA3 and Ventricular arrhythmia.